These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2642628)

  • 21. Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure.
    Colucci WS
    Am J Cardiol; 1989 Jan; 63(2):17A-22A. PubMed ID: 2909993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine.
    Hood WB
    Am J Cardiol; 1989 Jan; 63(2):46A-53A. PubMed ID: 2521268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure.
    Shekhar YC; Anand IS; Sarma R; Ferrari R; Wahi PL; Poole-Wilson PA
    Am J Cardiol; 1991 Apr; 67(8):732-6. PubMed ID: 2006623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-related hemodynamic, renal, and hormonal differences among patients with congestive heart failure.
    Cody RJ; Torre S; Clark M; Pondolfino K
    Arch Intern Med; 1989 May; 149(5):1023-8. PubMed ID: 2655542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [How to use PDE III inhibitors].
    Goto Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():49-56. PubMed ID: 17571365
    [No Abstract]   [Full Text] [Related]  

  • 26. Specific phosphodiesterase inhibition and maximal and submaximal exercise performance in patients with congestive heart failure.
    Katz S; Wahl J; Troha J; Sonnenblick EH; Le Jemtel TH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S45-8. PubMed ID: 2478792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.
    Floreani M; Fossa P; Gessi S; Mosti L; Borea PA; Dorigo P
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):109-18. PubMed ID: 12595951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myocardial and vascular actions of milrinone.
    Colucci WS
    Eur Heart J; 1989 Aug; 10 Suppl C():32-8. PubMed ID: 2680495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure.
    Packer M
    Circulation; 1988 Jun; 77(6 Pt 2):I64-73. PubMed ID: 2967129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure.
    Yamamoto T; Wada A; Ohnishi M; Tsutamoto T; Fujii M; Matsumoto T; Takayama T; Wang X; Kurokawa K; Kinoshita M
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():258S-262S. PubMed ID: 12193099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic achievements of phosphodiesterase inhibitors and the future.
    Jewitt DE
    Eur Heart J; 1989 Aug; 10 Suppl C():53-9. PubMed ID: 2680498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effective milrinone therapy to a Duchenne muscular dystrophy patient with advanced congestive heart failure].
    Matsumura T; Saito T; Miyai I; Nozaki S; Kang J
    Rinsho Shinkeigaku; 1999 Jun; 39(6):643-8. PubMed ID: 10502990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine.
    Thomas NJ; Carcillo JA; Herzer WA; Mi Z; Jackson EK
    J Pharmacol Exp Ther; 2001 Jan; 296(1):168-74. PubMed ID: 11123377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.
    Townend JN; Doran J; Lote CJ; Davies MK
    Br Heart J; 1995 May; 73(5):434-41. PubMed ID: 7786658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
    Dzau VJ
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):74-80. PubMed ID: 3037893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle.
    Silver PJ; Harris AL; Canniff PC; Lepore RE; Bentley RG; Hamel LT; Evans DB
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):530-40. PubMed ID: 2470989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure.
    Solter P; Sisson D; Thomas W; Goetze L
    J Pharmacol Exp Ther; 2000 Jun; 293(3):989-95. PubMed ID: 10869402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous milrinone in patients with severe congestive cardiac failure awaiting heart transplantation.
    Skoyles JR; Sherry KM; Price C
    J Cardiothorac Vasc Anesth; 1992 Apr; 6(2):222-5. PubMed ID: 1568013
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction).
    Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL
    Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.